<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826241</url>
  </required_header>
  <id_info>
    <org_study_id>999916005</org_study_id>
    <secondary_id>NCI-2012-02131</secondary_id>
    <secondary_id>16-C-N005</secondary_id>
    <nct_id>NCT00826241</nct_id>
  </id_info>
  <brief_title>Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma</brief_title>
  <official_title>A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CERN Foundation - Collaborative Ependymoma Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if lapatinib when given in combination
      with temozolomide can help to control ependymoma that has come back after treatment. The
      safety of this combination will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Temozolomide is designed to kill cancer cells by damaging deoxyribonucleic acid (DNA) (the
      genetic material of cells). This could cause the tumor cells to die.

      Lapatinib is designed to prevent or slow down the growth of cancer cells by blocking proteins
      inside the cancer cell, called the human epidermal growth factor receptor 2 (Her2/neu)
      receptor and the epidermal growth factor receptor (EGFR).

      Study Drug Administration:

      If you are found to be eligible to take part in this study, every day, you will take
      lapatinib by mouth once a day in the morning. You should take lapatinib 1 hour before or 1
      hour after eating, with at least 1 cup (about 8 oz.) of water.

      On Days 1-7 and 15-21 of each cycle, you will take temozolomide by mouth 1 time each day. You
      will start to take a lower dose of temozolomide for the first 2 cycles, then take a higher
      dose for Cycles 3 and beyond if you tolerate the treatment. It should be taken at least 2
      hours before and 2 hours after eating with 1 cup (about 8 oz.) of water.

      You should swallow temozolomide and/or lapatinib whole, one right after the other, without
      chewing either of the study drugs. If you vomit while taking temozolomide and lapatinib, you
      cannot take more capsules before the next scheduled dose. You should report any missed pills
      or trouble you have with taking the pills to your study doctor. Your study doctor will give
      you a form (patient diary) to fill out to keep track of your treatment. You will be asked to
      return your completed diary and pill bottles at each visit with your doctor.

      Each study &quot;cycle&quot; is 28 days.

      Study Visits:

      Every 2 weeks, blood (about 2-3 teaspoons) will be drawn for routine tests and to check your
      blood's ability to clot.

      Every 8 weeks, the following tests and procedures will be performed:

        -  You will have a physical exam, including measurement of your vital signs.

        -  You will have a neurological exam.

        -  Your performance status will be recorded.

        -  You will be asked about any drugs you may be taking and if you have experienced any side
           effects.

        -  You will complete the quality of life questionnaire.

        -  You will have an magnetic resonance imaging (MRI) scan to check the status of the
           disease.

        -  You will have either a multi-gated acquisition scan (MUGA) scan (if the doctor thinks it
           is needed) or an echocardiogram.

      Length of Study:

      You will be on study treatment for up to 2 years. You will be taken off study treatment early
      if the disease gets worse or you experience intolerable side effects.

      After you are off study, you may be able to continue taking lapatinib for as long as the
      doctor thinks it is in your best interest. Your doctor will discuss this with you.

      End-of-Study Visit:

      After you go off study treatment, you will have an end-of-study visit. At this visit, the
      following tests and procedures will be performed:

        -  You will have a physical exam.

        -  Your performance status will be recorded.

        -  You will be asked about any drugs you may be taking and if you have experienced any side
           effects.

        -  You will have a neurological exam.

        -  Blood (about 3 teaspoons) will be drawn for routine tests and to check your blood's
           ability to clot.

        -  You will complete the questionnaire.

        -  You will have an MRI scan to check the status of the disease.

        -  You will have either a MUGA scan (if the doctor thinks it is needed) or an
           echocardiogram.

      Long-Term Follow-up Visit:

      If you go off treatment (having completed the maximum 24 months on study drug treatment) and
      have stable disease or response, you will have an MRI scan to check the status of the disease
      every 2 months for first year after you are off study, then every 3 months for the second
      year, then every 4 months for the third year, and then every 6 months from then on.

      If you continue taking lapatinib after you have completed up to 24 months on study treatment,
      you will have a clinic visit and an MRI scan to check the status of the disease every 2
      months for as long as the doctor thinks it is needed. At the clinic visits, you will be asked
      how you are doing.

      If you went off study treatment because the disease got worse or you experienced intolerable
      side effects, after the end-of-study visit, the study staff will call you every 3 months from
      then on to check how you are doing. Each phone call will take about 5 minutes.

      This is an investigational study. Temozolomide is Food and Drug Administration (FDA) approved
      or commercially available for the treatment of tumors of the nervous system. Lapatinib is FDA
      approved and commercially available for the treatment of breast cancer. However, lapatinib is
      not FDA approved for the treatment of brain tumors. The use of lapatinib with temozolomide in
      the treatment of brain tumors and spinal tumors is investigational.

      Up to 50 patients will take part in this multicenter study. Up to 30 will be enrolled at MD
      Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Assessed every two months till disease progression, up to 4 years</time_frame>
    <description>Time to progression defined as progressive disease, toxicity at a level of severity that precludes the patient continuing on the protocol, or death. Progression is a 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Overall Response (Complete Response or Partial Response) Assessed by the MacDonald Criteria</measure>
    <time_frame>4 weeks</time_frame>
    <description>Anti-tumor activity as determined by the overall response (Complete response (CR) or partial response (PR)) was assessed by the MacDonald criteria. Complete response is complete resolution of all lesions. The patient cannot be on any corticosteroids with the exception of adrenal replacement doses. Partial response is â‰¥50% reduction in the sum of products of all measurable lesions over baseline sum observed using the same techniques as baseline. The patient must be on a stable or decreased dose of corticosteroids to be evaluable for response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-Serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 111 months and 26 days</time_frame>
    <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Brain Tumors</condition>
  <condition>Spinal Cord Tumors</condition>
  <arm_group>
    <arm_group_label>Temozolomide + Lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle.</description>
    <arm_group_label>Temozolomide + Lapatinib</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>Starting dose 1250 mg daily by mouth.</description>
    <arm_group_label>Temozolomide + Lapatinib</arm_group_label>
    <other_name>GW572016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven ependymoma or anaplastic ependymoma. There must be pathologic or
             imaging confirmation of tumor progression or regrowth. The patients histologic
             diagnosis must be confirmed on Central Pathology Review prior to registration Step 2.

          2. History and physical examination, including neurologic examination, within 2 weeks
             prior to registration.

          3. Patients must be able to undergo brain or spine magnetic resonance imaging (MRI) scans
             with intravenous gadolinium, based on tumor location(s) within 14 days prior to
             registration.

          4. Patients must be on a steroid dose that has been stable or decreasing for at least 5
             days. If the steroid dose is increased between the date of imaging and registration, a
             new baseline MRI is required.

          5. Karnofsky performance status &gt;/= 70

          6. Age &gt;/= 18

          7. Complete blood count (CBC)/differential obtained within 14 days prior to registration,
             with adequate bone marrow function defined as follows: 1) Absolute neutrophil count
             (ANC) &gt;/= 1,500/mm^3. 2) Platelets &gt;/= 100,000 cells/mm^3. 3) Hemoglobin &gt;/= 10.0
             gm/dL (Note: The use of transfusion or other intervention to achieve Hgb &gt;/= 10.0 is
             acceptable). 4) White blood cell count (WBC) &gt;/= 3,000/mcL.

          8. Adequate liver function within 14 days prior to registration, defined as follows:
             serum glutamic pyruvic transaminase (SGPT) [alanine aminotransferase (ALT)] &lt; 2.5
             times the upper limit of normal, Bilirubin &lt;/= 1.6 mg/dL

          9. Adequate renal function within 14 days prior to registration, defined as follows:
             Creatinine &lt; 1.7 mg/dL

         10. Patients must have recovered from the toxic effects of prior therapy, and there must
             be a minimum time of: 1) 28 days from the administration of any investigational agent.
             2) 28 days from administration of prior cytotoxic therapy with the following
             exceptions: (a) 14 days from administration of vincristine. (b) 42 days from
             administration of nitrosoureas. (c) 21 days from administration of procarbazine.

         11. ( 11. continued) 3) 7 days from administration of non-cytotoxic agents [e.g.,
             interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not
             count)]. 4) 28 days from prior radiation therapy.

         12. Patients must have recovered from the effects of surgery and a minimum of 14 days must
             have elapsed from the day of surgery to the day of registration. For core or needle
             biopsy, a minimum of 7 days must have elapsed prior to registration.

         13. Residual disease following resection of recurrent tumor is not mandated for
             eligibility into the study. To best assess the extent of residual disease
             post-operatively, an MRI should be done no later than 96 hours in the immediate
             postoperative period or at least 4 weeks postoperatively, within 14 days prior to
             registration. If the &quot; within 96-hour of surgery &quot; scan is more than 14 days before
             registration, the scan needs to be repeated.

         14. Patients must sign study-specific informed consent and authorization for the release
             of their protected health information prior to registration. Patients must be
             registered in the MD Anderson Cancer Center Office of Multicenter Clinical Research
             (MDACC OMCR) database prior to treatment with study drug.

         15. Women of childbearing potential must have a negative beta-human chorionic gonadotropin
             (HCG) pregnancy test documented within 14 days prior to registration.

         16. Women of childbearing potential and male participants must practice adequate
             contraception

         17. All patients must have an left ventricular ejection fraction (LVEF) measurement of at
             least 50% by Echo or MUGA (if clinically indicated) within 14 days prior to
             registration. The method used for LVEF assessment in an individual subject must be the
             same throughout the trial.

        Exclusion Criteria:

          1. Prior invasive malignancy that is not the ependymoma (except non-melanomatous skin
             cancer or carcinoma in situ of the cervix) unless the patient has been disease free
             and off therapy for that disease for a minimum of 3 years

          2. Transmural myocardial infarction or unstable angina within 3 months prior to study
             registration

          3. Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations
             of &gt;/= 2 mm using the analysis of an electrocardiography (EKG) performed within 14
             days prior to registration

          4. New York Heart Association grade II or greater congestive heart failure requiring
             hospitalization within 12 months prior to registration

          5. History of stroke or transient ischemic attack within 3 months prior to registration.

          6. Inadequately controlled hypertension (systolic blood pressure &gt; 140 mm Hg and/or
             diastolic blood pressure &gt; 90 mm Hg despite antihypertensive medication)

          7. History of cerebral vascular accident (CVA) within 3 months prior to registration

          8. Serious and inadequately controlled cardiac arrhythmia

          9. Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection)

         10. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of
             registration

         11. Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease
             Control and Prevention (CDC) definition; note, however, that HIV testing is not
             required for entry into this protocol. The need to exclude patients with acquired
             immunodeficiency syndrome (AIDS) from this protocol is necessary because the
             treatments involved in this protocol may be significantly immunosuppressive.

         12. Pregnant or nursing women because of concern of fetal/infant exposure to these agents

         13. Any condition that impairs ability to swallow pills (e.g., gastrointestinal tract
             disease resulting in an inability to take oral medication or a requirement for
             intravenous (IV) alimentation, prior surgical procedures affecting absorption, active
             peptic ulcer disease).

         14. Patients cannot be receiving enzyme-inducing anti-epileptic Drugs (EIAEDs) nor any
             other Image result for CYP3A4 Cytochrome P450 3A4 (CYP3A4) inducers such as rifampin
             or St. John's wort beginning at least 14 days prior to registration Step 2.

         15. Patients cannot be receiving CYP3A4 inhibitors beginning at least 7 days prior to
             registration Step 2.

         16. Patients must not have current active hepatic or biliary disease (with exception of
             patients with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver
             disease per investigator assessment).

         17. Patients cannot be receiving HAART (Highly Active Anti-Retroviral Therapy) therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Penas-Prado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 20, 2009</study_first_submitted>
  <study_first_submitted_qc>January 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <results_first_submitted>February 4, 2019</results_first_submitted>
  <results_first_submitted_qc>March 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2019</results_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Mark Gilbert, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Brain Tumor</keyword>
  <keyword>Central Nervous System</keyword>
  <keyword>CNS</keyword>
  <keyword>Spinal Cord Tumor</keyword>
  <keyword>Anaplastic Ependymoma</keyword>
  <keyword>Supratentorial Ependymoma</keyword>
  <keyword>Infratentorial Ependymoma</keyword>
  <keyword>Spinal Cord Ependymoma</keyword>
  <keyword>Lapatinib</keyword>
  <keyword>GW572016</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Temodar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT00826241/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT00826241/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Temozolomide + Lapatinib</title>
          <description>Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
Temozolomide: Starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle.
Lapatinib: Starting dose 1250 mg daily by mouth.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal from Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-reportable(not qualify as Gr. 5 SAE)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient refused follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Could not obtain records</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pt unable to proceed to registration</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pt opt not to proceed w/trmt</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Temozolomide + Lapatinib</title>
          <description>Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
Temozolomide: Starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle.
Lapatinib: Starting dose 1250 mg daily by mouth.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.77" spread="15.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression</title>
        <description>Time to progression defined as progressive disease, toxicity at a level of severity that precludes the patient continuing on the protocol, or death. Progression is a 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>Assessed every two months till disease progression, up to 4 years</time_frame>
        <population>8 patients were not evaluable/replaced: 2 - withdrew,1 - non-compliant, 2 - screen failures, 1 - could not obtain records, 1 - opted not to proceed with treatment, and 1 - unable to proceed to registration.</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide + Lapatinib</title>
            <description>Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
Temozolomide: Starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle.
Lapatinib: Starting dose 1250 mg daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time to progression defined as progressive disease, toxicity at a level of severity that precludes the patient continuing on the protocol, or death. Progression is a 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).</description>
          <population>8 patients were not evaluable/replaced: 2 - withdrew,1 - non-compliant, 2 - screen failures, 1 - could not obtain records, 1 - opted not to proceed with treatment, and 1 - unable to proceed to registration.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="5.2" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Overall Response (Complete Response or Partial Response) Assessed by the MacDonald Criteria</title>
        <description>Anti-tumor activity as determined by the overall response (Complete response (CR) or partial response (PR)) was assessed by the MacDonald criteria. Complete response is complete resolution of all lesions. The patient cannot be on any corticosteroids with the exception of adrenal replacement doses. Partial response is â‰¥50% reduction in the sum of products of all measurable lesions over baseline sum observed using the same techniques as baseline. The patient must be on a stable or decreased dose of corticosteroids to be evaluable for response.</description>
        <time_frame>4 weeks</time_frame>
        <population>8 patients were not evaluable/replaced: 2 - withdrew,1 - non-compliant, 2 - screen failures, 1 - could not obtain records, 1 - opted not to proceed with treatment, and 1 - unable to proceed to registration.</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide + Lapatinib</title>
            <description>Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
Temozolomide: Starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle.
Lapatinib: Starting dose 1250 mg daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Overall Response (Complete Response or Partial Response) Assessed by the MacDonald Criteria</title>
          <description>Anti-tumor activity as determined by the overall response (Complete response (CR) or partial response (PR)) was assessed by the MacDonald criteria. Complete response is complete resolution of all lesions. The patient cannot be on any corticosteroids with the exception of adrenal replacement doses. Partial response is â‰¥50% reduction in the sum of products of all measurable lesions over baseline sum observed using the same techniques as baseline. The patient must be on a stable or decreased dose of corticosteroids to be evaluable for response.</description>
          <population>8 patients were not evaluable/replaced: 2 - withdrew,1 - non-compliant, 2 - screen failures, 1 - could not obtain records, 1 - opted not to proceed with treatment, and 1 - unable to proceed to registration.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-Serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</title>
        <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 111 months and 26 days</time_frame>
        <population>8 patients were not evaluable/replaced: 2 - withdrew,1 - non-compliant, 2 - screen failures, 1 - could not obtain records, 1 - opted not to proceed with treatment, and 1 - unable to proceed to registration.</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide + Lapatinib</title>
            <description>Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
Temozolomide: Starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle.
Lapatinib: Starting dose 1250 mg daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-Serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</title>
          <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <population>8 patients were not evaluable/replaced: 2 - withdrew,1 - non-compliant, 2 - screen failures, 1 - could not obtain records, 1 - opted not to proceed with treatment, and 1 - unable to proceed to registration.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 111 months and 26 days.</time_frame>
      <desc>8 patients were not evaluable/replaced: 2 - withdrew,1 - non-compliant, 2 - screen failures, 1 - could not obtain records, 1 - opted not to proceed with treatment, and 1 - unable to proceed to registration.</desc>
      <group_list>
        <group group_id="E1">
          <title>Temozolomide + Lapatinib</title>
          <description>Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
Temozolomide: Starting dose 125 mg/m^2 daily by mouth on days 1-7 &amp; 15-21 of a 28 day cycle.
Lapatinib: Starting dose 1250 mg daily by mouth.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection)(ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU : Bladder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>(documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L) : Skin (cellulitis)</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Skin (cellulitis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Urinary tract NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) : Extremity-lower</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, left hip)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy - possibly related to cancer treatment (Specify,B-cell/large cell lymphoma)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Specify, __)</sub_title>
                <description>upper respiratory congestion -stable bronchitis vs pneumonia</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/bleeding associated with surgery, intra-operative or postoperative</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - Other (Specify, BUN)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Blood/Bone Marrow - Other (Specify,elevated bilirubin)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="352" subjects_affected="30" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other (Specify, left thigh)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other (Specify,mild peripheral edema)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General - Other (Specify, sinus tachycardia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia : Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear - Other (Specify, fluttering sensation)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Auditory/Ear - Other (Specify, hearing loss; present at baseline)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hearing: patients with/without baseline audiogram and enrolled in a monitoring program</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hearing: patients without baseline audiogram and not enrolled in a monitoring program</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid appearance (e.g., moon face, buffalo hump, centripetal obesity, cutaneous striae)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thyroid function, high (hyperthyroidism, thyrotoxicosis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thyroid function, low (hypothyroidism)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Other (Specify, Dysconjugate gaze. Present after surgery.)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Other (Specify, left hemaniopsia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Other (Specify, vision loss left eye)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Other (Specify, visual impairment)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Ophthalmoplegia/diplopia (double vision)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="82" subjects_affected="32" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Herpes Zoster - pain around bra line w/ out rash. Has Zoster before in same area.</description>
                <counts group_id="E1" events="46" subjects_affected="19" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastritis (including bile reflux gastritis)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, abdominal distension)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, cramps in pelvis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify,gastrointestinal pain (intermittent))</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, mucositis oral)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, rectal discomfort)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other (Specify, stool incontinence)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI : Lower GI NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI : Oral cavity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI : Rectum</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other (Specify, gums)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Incontinence, anal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) :</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam) : Oral cavity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic) : Oral cavity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="82" subjects_affected="32" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, stomach pain)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Abdomen NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Oral cavity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="24" subjects_affected="10" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other (Specify, constipation)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other (Specify, fatigue)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other (Specify, hyposmia: reduced ability to smell)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other (Specify,insomnia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Edema: head and neck</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="102" subjects_affected="39" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Pain NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Syndromes - Other (Specify, tremors; left hand)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy/Immunology - Other (Specify, environmental allergic dry cough)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other (Specify, bronchial infection)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection - Other (Specify,Other, toe fungal)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection - Other (Specify,shingles)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection - Other (Specify, Varicella Zoster)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Esophagus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : External ear (otitis externa)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils</sub_title>
                <description>Foreign body (e.g., graft, implant, prosthesis, stent)</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Skin (cellulitis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Upper airway NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils : Urinary tract NOS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC : Bladder (urinary)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC : Urinary tract NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Opportunistic infection associated with &gt;=Grade 2 Lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of Grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Wound complication, non-infectious</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="54" subjects_affected="17" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="50" subjects_affected="16" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesteremia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="22" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="190" subjects_affected="25" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="444" subjects_affected="35" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="154" subjects_affected="17" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="174" subjects_affected="23" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="86" subjects_affected="22" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="24" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, Akaline Phosphatase Serum Low)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, Albumin serum high)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify,alkaline phosphatase count low)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify,amylase serum low)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify,AST-SGOT serum low)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, BUN)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, BUN count increased)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, BUN serum high)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, BUN serum low)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, carbon dioxide)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, carbon dioxide count increased)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, carbon dioxide serum high)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, chloride count decreased)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, chloride serum high)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, chloride serum low)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, CO2 count increased)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, CO2 high serum)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, creatinine count decreased)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, creatinine serum low)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, CSF Total Nucleated Cells Increased)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, hyperalbumin)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, hyperphosphatemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, LDH)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, LDH serum increased)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, LDH count decreased)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, LDH count increased)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, LDH serum high)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, LDH serum low)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, phosphorous serum high)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, protein count decreased)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, protein serum low)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, SGOT decreased count)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, total protein serum low)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, uric acid serum low)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other (Specify, vitamin B12 deficiency)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="22" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="18" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum-high (hypertriglyceridemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="26" subjects_affected="7" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spine-range of motion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Extremity-lower (gait/walking)</sub_title>
                <counts group_id="E1" events="42" subjects_affected="18" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) : Extremity-lower</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) : Extremity-upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) : Facial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) : Left-sided</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) : Right-sided</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) : Whole body/generalized</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specify, difficulty walking)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specify, intermittent back pain)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specify, left hand)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specify, lower extremity)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specify, paresthesia, left hand (carpal tunnel type syndrome)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other (Specify, right back tightness)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, back and right arm)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, joint pain)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, left anterior iliac spine)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, left leg)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, left sacrum pain)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, leg pain)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, musculoskeletal-back)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, pain-pelvis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, RUQ)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, severe pain left thigh)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Back</sub_title>
                <counts group_id="E1" events="28" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Bone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Chest/thorax NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Extremity-limb</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Joint</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Muscle</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Neck</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pain : Tumor pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Extrapyramidal/involuntary movement/restlessness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neurology - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="32" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial : CN VII Motor-face; Sensory-taste</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial : CN VIII Hearing and balance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="52" subjects_affected="22" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, headaches)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, neuralgia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Head/headache</sub_title>
                <counts group_id="E1" events="38" subjects_affected="17" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pyramidal tract dysfunction</sub_title>
                <description>(e.g., increased tone, hyperreflexia, positive Babinski, decreased fine motor coordination)</description>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g., dysphasia or aphasia)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mood alteration :</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mood alteration : Agitation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mood alteration : Anxiety</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mood alteration : Depression</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other (Specify, urinary tract infection)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Libido</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Obstruction, GU : Prostate</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Breast</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bronchospasm, wheezing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="24" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other (Specify, nose)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain : Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other (Specify, sinus congestion)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria (e.g., hoarseness, loss or alteration in voice, laryngitis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify, _)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify,steroid-related acne)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify, paresthesia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain - Other (Specify, pain in the rash area chest and the back)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="22" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="48" subjects_affected="15" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="42" subjects_affected="16" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash: erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin breakdown/decubitus ulcer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/bleeding associated with surgery, intra-operative or postoperative</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Gilbert</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>240-760-6023</phone>
      <email>gilbertmr@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

